{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:18:21Z","timestamp":1792016301298,"version":"4.4.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1016\/j.ejca.2008.12.010","type":"journal-article","created":{"date-parts":[[2009,1,21]],"date-time":"2009-01-21T20:10:08Z","timestamp":1232568608000},"page":"765-773","source":"Crossref","is-referenced-by-count":79,"title":["EORTC-GU group expert opinion on metastatic renal cell cancer"],"prefix":"10.1016","volume":"45","author":[{"given":"Theo M.","family":"de Reijke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Bellmunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hein","family":"van Poppel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Marreaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Aapro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2008.12.010_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2005.03.7234","article-title":"Treatment options in metastatic renal carcinoma: an embarrassment of riches","volume":"24","author":"Vogelzang","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.12.010_bib2","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.eururo.2005.11.035","article-title":"2004 WHO classification of the renal tumors of the adults","volume":"49","author":"Lopez-Beltran","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2008.12.010_bib3","unstructured":"Oxford Centre for Evidence-based Medicine. <http:\/\/www.cebm.net\/> [accessed 30.01.08]."},{"key":"10.1016\/j.ejca.2008.12.010_bib4","series-title":"European Association of Urology Guidelines: Renal Cell Carcinoma","author":"Ljungberg","year":"2007"},{"key":"10.1016\/j.ejca.2008.12.010_bib5","unstructured":"National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines on Kidney Cancer, version 1; 2008."},{"key":"10.1016\/j.ejca.2008.12.010_bib6","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/cncr.11234","article-title":"Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials","volume":"97","author":"Leibovich","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2008.12.010_bib7","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1097\/01.ju.0000095541.10333.a7","article-title":"A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma","volume":"170","author":"Frank","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.ejca.2008.12.010_bib8","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1200\/JCO.2001.19.6.1649","article-title":"Improved prognostication of renal cell carcinoma using an integrated staging system","volume":"19","author":"Zisman","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.12.010_bib9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1464-410X.2007.07170.x","article-title":"Patients with distant metastases from renal cell carcinoma can be accurately identified: external validation of a new nomogram","volume":"101","author":"Hutterer","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.ejca.2008.12.010_bib10","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.eururo.2006.12.031","article-title":"A review on follow-up strategies for renal cell carcinoma after nephrectomy","volume":"51","author":"Skolarikos","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2008.12.010_bib11","doi-asserted-by":"crossref","unstructured":"Brouwers AH, Jager PL. Radionuclide imaging in renal cell carcinoma. In: De la Rosette J, Manyak MJ, Harisinghan MG, Wijkstra H, editors. Imaging in oncological urology; 2008. p. 510.","DOI":"10.1007\/978-1-84628-759-6_8"},{"key":"10.1016\/j.ejca.2008.12.010_bib12","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.eururo.2007.01.061","article-title":"Molecular positron emission tomography and PET\/CT imaging in urological malignancies","volume":"51","author":"Powles","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2008.12.010_bib13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11934-007-0019-3","article-title":"Contemporary imaging modalities for the surveillance of patients with renal cell carcinoma","volume":"8","author":"Tollefson","year":"2007","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.ejca.2008.12.010_bib14","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1200\/JCO.2007.15.6331","article-title":"Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma","volume":"32","author":"Schmidinger","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.12.010_bib15","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1200\/JCO.2008.18.5439","article-title":"Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?","volume":"32","author":"Lenihan","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.12.010_bib16","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1158\/1078-0432.CCR-06-1922","article-title":"Biomarkers for monitoring antiangiogenic therapy","volume":"15","author":"Bhatt","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2008.12.010_bib17","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/j.ejca.2006.04.023","article-title":"To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound","volume":"42","author":"Lamuraglia","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2008.12.010_bib18","doi-asserted-by":"crossref","first-page":"770s","DOI":"10.1158\/1078-0432.CCR-06-1921","article-title":"Dynamic contrast-enhanced magnetic resonance imaging for assessing tumour vascularity and vascular effects of targeted therapies in renal cell carcinoma","volume":"13","author":"Rosen","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2008.12.010_bib19","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0140-6736(01)06103-7","article-title":"Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal cell carcinoma: a randomised trial","volume":"358","author":"Mickisch","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2008.12.010_bib20","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa003013","article-title":"Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal cell cancer","volume":"345","author":"Flanigan","year":"2001","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2008.12.010_bib21","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/01.ju.0000110610.61545.ae","article-title":"Cytoreductive nephrectomy in patients with metastatic renal cell cancer: a combined analysis","volume":"171","author":"Flanigan","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.ejca.2008.12.010_bib22","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJM200112063452317","article-title":"Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma","volume":"345","author":"Pantuck","year":"2001","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2008.12.010_bib23","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0022-5347(17)35514-3","article-title":"Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy","volume":"150","author":"Marcus","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.ejca.2008.12.010_bib24","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJM199804303381804","article-title":"Interferon gamma-1b compared with placebo in metastatic renal cell carcinoma: Canadian Urologic Oncology Group","volume":"338","author":"Gleave","year":"1998","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2008.12.010_bib25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00005392-199907000-00011","article-title":"Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place","volume":"162","author":"Wagner","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.ejca.2008.12.010_bib26","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1089\/end.2006.20.891","article-title":"Conventional and hand-assisted laparoscopic radical nephrectomy: comparative analysis of 271 cases","volume":"20","author":"Matin","year":"2006","journal-title":"J Endourol"},{"key":"10.1016\/j.ejca.2008.12.010_bib27","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.juro.2007.01.136","article-title":"The evolving role of surgery for advanced renal cell carcinoma in the age of molecular targeted therapy","volume":"177","author":"Rini","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.ejca.2008.12.010_bib28","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.juro.2008.05.006","article-title":"Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma","volume":"180","author":"Eggener","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.ejca.2008.12.010_bib29","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3816\/CGC.2006.n.042","article-title":"Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases","volume":"5","author":"Rini","year":"2006","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ejca.2008.12.010_bib30","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1148\/radiology.138.3.7465831","article-title":"Embolization of renal carcinoma","volume":"138","author":"Wallace","year":"1981","journal-title":"Radiology"},{"key":"10.1016\/j.ejca.2008.12.010_bib31","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/003655999750015934","article-title":"The role of arterial embolization in renal cell carcinoma","volume":"33","author":"Kalman","year":"1999","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.ejca.2008.12.010_bib32","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s003300050969","article-title":"Preoperative embolization of bone metastases from renal cell carcinoma","volume":"10","author":"Chatziioannou","year":"2000","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ejca.2008.12.010_bib33","first-page":"223","article-title":"Arterial embolization of bone metastases: is it worthwhile?","volume":"81","author":"Layalle","year":"1998","journal-title":"J Belge Radiol"},{"key":"10.1016\/j.ejca.2008.12.010_bib34","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.radonc.2005.03.022","article-title":"Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma","volume":"77","author":"Wers\u00e4ll","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejca.2008.12.010_bib35","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0360-3016(02)04379-1","article-title":"A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases","volume":"55","author":"O\u2019Neill","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2008.12.010_bib36","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s00345-004-0471-3","article-title":"Treatment of brain metastases in renal cell carcinoma: radiotherapy, radiosurgery, or surgery?","volume":"23","author":"Muacevic","year":"2005","journal-title":"World J Urol"},{"key":"10.1016\/j.ejca.2008.12.010_bib37","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1002\/cncr.21410","article-title":"A phase II trial of palliative radiotherapy for metastatic renal cell carcinoma","volume":"104","author":"Lee","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2008.12.010_bib38","first-page":"1759","article-title":"Clinical value of bisphosphonates in cancer therapy","volume":"27","author":"L\u00fcftner","year":"2007","journal-title":"Anticancer Res"},{"issue":"18S","key":"10.1016\/j.ejca.2008.12.010_bib39","article-title":"Activity of MVA 5T4 alone or in combination with either interleukin-2 (IL-2) or interferon-a (IFN) in patients (Pts) with metastatic renal cell cancer (MRCC)","volume":"25","author":"Cao","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.12.010_bib40","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/sj.bjc.6604266","article-title":"Vaccination of metastatic renal cell carcinoma patients with autologous tumor-derived vitespen vaccine: clinical findings","volume":"98","author":"Jonasch","year":"2008","journal-title":"Brit J Cancer"},{"key":"10.1016\/j.ejca.2008.12.010_bib41","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.5101","article-title":"Vaccination of renal cell cancer (RCC) patients with modified vaccinia ankara delivering the tumor antigen 5T4 (Trovax) administered+low dose interleukin-2 (IL-2): a phase II trial","author":"Hernandez-McClain","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.12.010_bib42","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(08)60697-2","article-title":"An adjuvant autologous therapeutic vaccine (HSPCC-96; Vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial","volume":"372","author":"Wood","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2008.12.010_bib43","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1158\/1078-0432.CCR-05-2253","article-title":"A phase I trial of vaccination of CA9-derived peptides from HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma","volume":"12","author":"Uemura","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2008.12.010_bib44","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.12.010_bib45","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/1097-0142(19870201)59:3+<647::AID-CNCR2820591313>3.0.CO;2-#","article-title":"Interferon treatment of renal cell carcinoma. Current status and future prospects","volume":"59","author":"Krown","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2008.12.010_bib46","first-page":"30","article-title":"The role of biological response modifiers in metastatic renal cell carcinoma","volume":"15","author":"Muss","year":"1988","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2008.12.010_bib47","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/jama.1994.03510360033032","article-title":"Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high dose bolus interleukin 2","volume":"271","author":"Rosenberg","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2008.12.010_bib48","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1200\/JCO.2003.02.122","article-title":"Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cell cancer","volume":"21","author":"Yang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.12.010_bib49","doi-asserted-by":"crossref","first-page":"716s","DOI":"10.1158\/1078-0432.CCR-06-1872","article-title":"Update on the application of interleukin-2 in the treatment of renal cell carcinoma","volume":"13","author":"McDermott","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2008.12.010_bib50","first-page":"CD001425","article-title":"Immunotherapy for advanced renal cell cancer","volume":"1","author":"Coppin","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejca.2008.12.010_bib51","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199804303381805","article-title":"Recombinant human interleukin-2, recombinant interferon-alfa 2a, or both in metastatic renal-cell carcinoma: Groupe Francaise d\u2019Immunotherapie","volume":"338","author":"Negrier","year":"1998","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2008.12.010_bib52","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1200\/JCO.2005.03.206","article-title":"Randomized phase III trial of high-dose interleukin 2 versus subcutaneous interleukin 2 and interferon in patients with metastatic renal cell carcinoma","volume":"23","author":"McDermott","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.12.010_bib53","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1002\/cncr.23056","article-title":"Medroxyprogesterone, interferon alfa-2a, interleukin 2 or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis","volume":"110","author":"Negrier","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2008.12.010_bib54","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/annonc\/mdj133","article-title":"Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review","volume":"17","author":"Schoffski","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2008.12.010_bib55","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1464-410X.2006.06589.x","article-title":"Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents","volume":"99","author":"Bellmunt","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.ejca.2008.12.010_bib56","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2008.12.010_bib57","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2008.12.010_bib58","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.5024","article-title":"Sunitinib versus interferon-alpha as first line treatment of metastatic renal cell carcinoma: updated results and analysis of prognostic factors","volume":"25","author":"Motzer","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.12.010_bib59","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.5024","article-title":"Overall survival with sunitinib versus interferon-alfa as first-line treatment of metastatic renal cell carcinoma","volume":"26","author":"Figlin","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.12.010_bib60","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.5025","article-title":"Randomized phase II trial of first line treatment with sorafenib versus ifn in patients with advanced renal cell carcinoma: final results","volume":"25","author":"Szczylik","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.12.010_bib61","doi-asserted-by":"crossref","unstructured":"Bellmunt J, Negrier S, Escudier B, Awada A, Aapro M. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. Crit Rev Oncol\/Hematol 2008 [Epub ahead of print].","DOI":"10.1016\/S1040-8428(13)70121-5"},{"key":"10.1016\/j.ejca.2008.12.010_bib62","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2008.12.010_bib63","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1200\/JCO.2008.16.9847","article-title":"Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206","volume":"26","author":"Rini","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.12.010_bib64","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1200\/JCO.2007.11.5154","article-title":"Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer","volume":"25","author":"Bukowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.12.010_bib65","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2008.12.010_bib66","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2007.13.3223","article-title":"Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma","volume":"26","author":"Choueieri","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.12.010_bib67","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2008.12.010_bib68","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"RAD001 vs placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: results from a randomized, double-blind, multicenter phase III study","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2008.12.010_bib69","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.5035","article-title":"Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell cancer: updated results and analysis of circulating biomarkers","volume":"25","author":"George","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.12.010_bib70","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.5038","article-title":"Sequential use of sorafenib and sunitinib in renal cell carcinoma: retrospective analysis in 90 patients","volume":"25","author":"Sablin","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.12.010_bib71","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.5106","article-title":"Sequential therapy with sorafenib and sunitinib in renal cell carcinoma","volume":"25","author":"Dham","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804908010307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804908010307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T09:44:02Z","timestamp":1709977442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804908010307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":71,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S0959804908010307"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2008.12.010","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}